Frontline ALK, EGFR Inhibition in Non-Small Cell Lung Cancer

preview_player
Показать описание
Panelists discuss the frontline administration of ALK and EGFR inhibitors for patients with advanced non-small cell lung caner.

  1. OncLive
  2. cancer
  3. oncology
  4. Non-small Cell Lung Cancer (Disease Or Medical Condition)
  5. Epidermal Growth Factor Receptor (Protein)
  6. Anaplastic Lymphoma Kinase
Рекомендации по теме
Frontline ALK, EGFR 0:05:54

Frontline ALK, EGFR Inhibition in Non-Small Cell Lung Cancer

EGFR inhibitors in 0:18:06

EGFR inhibitors in mutation (+) patients: Current therapeutic strategies in the frontline setting

Dr. Velcheti on 0:01:42

Dr. Velcheti on Potential of Alectinib in Frontline ALK-Positive NSCLC

Osimertinib As Frontline 0:06:51

Osimertinib As Frontline Therapy in EGFR-Positive NSCLC

Targeted treatment with 0:20:24

Targeted treatment with EGFR TKIs: Front line options

Targeting ALK - 0:45:52

Targeting ALK - From Discovery to Frontline Treatment

Front-line targeted therapy 0:17:55

Front-line targeted therapy for advanced EGFR-positive disease

Targeting EGFR and 0:02:51

Targeting EGFR and ALK mutations

EGFR+ Non–Small Cell 0:03:52

EGFR+ Non–Small Cell Lung Cancer: Frontline Options

Adjuvant EGFR Inhibition 0:08:44

Adjuvant EGFR Inhibition in Patients With NSCLC

Dr. West on 0:00:55

Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC

DEBATE: ALK positive 0:13:28

DEBATE: ALK positive NSCLC - Front line therapy - Crizotinib

A Case of 0:05:55

A Case of EGFR-Mutant Non–Small Cell Lung Cancer

ALK Inhibition in 0:08:37

ALK Inhibition in NSCLC

EGFR & ALK/ROS1 0:08:25

EGFR & ALK/ROS1 Testing in Squamous NSCLC

Next-Generation Targeted Therapies 0:07:44

Next-Generation Targeted Therapies in Non-Small Cell Lung Cancer

Next-generation ALK inhibitors: 0:01:42

Next-generation ALK inhibitors: treatment sequencing and resistance

Development of ALK 0:04:37

Development of ALK Inhibitors in Advanced Non-Small Cell Lung Cancer

Plasma Testing for 0:04:09

Plasma Testing for NSCLC EGFR & ALK Mutations

How Do the 0:04:58

How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?

DEBATE: ALK positive 0:11:38

DEBATE: ALK positive NSCLC - Front line therapy - Ceritinib

Second-Generation ALK Inhibitors 0:07:11

Second-Generation ALK Inhibitors in Non-Small Cell Lung Cancer

Newer EGFR Inhibitors 0:07:31

Newer EGFR Inhibitors in NSCLC

Research Investigates Role 0:02:08

Research Investigates Role of Antiangiogenic Agents and Checkpoint Inhibitors in EGFR NSCLC